Our anti-LDHD antibody cited in a study on soft-tissue sarcoma research

Kim H, Ronai ZA. PRMT5 function and targeting in cancer. Cell Stress. 2020 Jul 13;4(8):199-215.

Soft tissue sarcoma (STS) is a rare type of cancer that starts as a growth of cells in the body's soft tissues including muscle, fat, blood vessels, nerves, tendons, and linings of the joints.

Patients with advanced STS have few therapeutic options. Recent studies demonstrated that the protein arginine methyltransferase 5 (PRMT5), an anticancer target, regulates STS cell metabolism and thus represents a potential therapeutic target for STS.

PRMT5 is a member of the nine-member PRMT family enzymes, which serve as “writers” of post-translational modifications (PTMs) controlling oncogenic processes, including tumor intrinsic and extrinsic microenvironmental signaling pathways.

The main goal of the study was to investigate the antitumoral effects of PRMT5 inhibition in STS.

Our anti-LDHD Triple A polyclonal antibody was used in western blot (WB) on sarcoma cell lines as one of the critical proteins involved in glycolysis.